Click Here to return To Results

 

Salvage Therapy for Primary CNS Lymphoma with a Combination of Rituximab and Temozolomide Neurol 63:901-903, Enting,R.H.,et al, 2004 See this aricle in Pubmed Article Abstract The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69n years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.

Related Tags

(click to filter results - removes previous filter) lymphoma lymphoma involving CNS lymphoma,primary of CNS monoclonal antibodies neoplasm,primary of CNS-treatment of old age,neurology of rituximab temozolomide treatment of neurologic disorder

Click Here to return To Results